Wednesday, June 15, 2016
Aethlon Medical, Inc., announced that U.S. Patent Number 9,364,601 (the "601 Patent"), related to methods for capturing an exosome from a patient, has been issued to the Company by the United States Patent and Trademark Office. The 601 Patent is an important addition to Aethlon's patent portfolio as it protects lectin-based exosome harvesting, diagnostics and therapeutic applications. In recent years, exosomes have emerged to become significant biomarker and therapeutic targets underlying a wide range of disease conditions, including cancer.
The 601 Patent covers methods of capturing exosomes whereby a patient for exosome capture is identified and an exosome from the patient is bound to a surface that comprises a lectin thereby capturing the exosome. The 601 Patent also covers methods of capturing an exosome whereby an exosome from a patient is contacted with an affinity device that comprises an affinity absorbent comprising a lectin thereby capturing the exosome on the affinity absorbent. The claims of the 601 Patent are not limited to the type of lectin, form of bodily fluid, or disease indication.
"Beyond expanding our intellectual property portfolio, the issuance of this patent reinforces our pioneering diagnostic and therapeutic strategies underlying the emerging field of exosome biology," stated Aethlon chairman and CEO, Jim Joyce.
Source : finance.yahoo.com
